MajorAntituberculous antibiotic×Reversible P2Y12 receptor inhibitor
Updated · Methodology
Mechanism
Strong CYP3A4 inducer – ticagrelor falls 86%. Antiplatelet effect lost – stent thrombosis risk.
Symptoms
Stent thrombosis, MI.
Management
Combination contraindicated. Alternative – clopidogrel or prasugrel.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- FDA: Brilinta (ticagrelor) prescribing information, Section 4.3 (2015)
- AEMPS: Ficha técnica: Ticagrelor (nº registro 89536), sección 4.5 (2026)– AEMPS, CIMA, nº registro 89536, sección 4.5